Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSQN9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,374
Award facts
- Contract value 100% obligated
- $15,373.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $15,373.56 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on December 5, 2025, with an ultimate completion date of December 29, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract with the Defense Logistics Agency, which was established on November 13, 2025, with a $499,999,999 ceiling value and a completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's medical supply chain, distributing a comprehensive portfolio that includes specialty surgical products, branded and generic medications, biologics, and medical consumables to military healthcare facilities. The company's established performance across numerous delivery orders spanning diverse therapeutic categories, combined with its status as a regional prime vendor contractor under the $30.3 billion PPV-G GEN V acquisition strategy, positions it as a key provider supporting the military's recurring pharmaceutical and medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FSQN9?
SPE2DR26FSQN9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FSQN9 worth?
The government has obligated $15,374 on SPE2DR26FSQN9.
Is contract SPE2DR26FSQN9 an order under another contract?
Yes. SPE2DR26FSQN9 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQN9 competed?
The extent of competition for SPE2DR26FSQN9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award